Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$463.15 USD
+1.39 (0.30%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $463.00 -0.15 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$463.15 USD
+1.39 (0.30%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $463.00 -0.15 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results.
Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.
Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%
by Zacks Equity Research
Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.
Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View
by Zacks Equity Research
Perrigo (PRGO) reports mixed third-quarter 2019 results. The Rx segment continues to witness recovery. Stock down.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise
by Zacks Equity Research
Celgene (CELG) beats on earnings and revenues in the third quarter of 2019 on strong performance from Otezla and Revlimid.
Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.
Will Vertex Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Vertex Pharmaceuticals.
Vertex Pharmaceuticals (VRTX) Beats Q3 Earnings Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 7.89% and -0.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Columbia Sportswear, Boot Barn, Vertex Pharmaceuticals, Upland Software and Spotify Technology
by Zacks Equity Research
Zacks.com featured highlights include: Columbia Sportswear, Boot Barn, Vertex Pharmaceuticals, Upland Software and Spotify Technology
Looking for an Earnings Beat? 5 Top Picks
by Sanghamitra Saha
5 top-ranked stocks likely to beat on earnings are great investment picks for stellar gains.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, PulteGroup, Skyworks Solutions, Lennar and Kansas City Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, PulteGroup, Skyworks Solutions, Lennar and Kansas City Southern
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
5 Top Volatility-Defying S&P 500 Stocks of Past Month
by Nalak Das
Year to date, the benchmark S&P 500 Index has rallied 20.1%, an impressive performance after a disappointing 2018, when it lost 6.6%.
Top Ranked Momentum Stocks to Buy for October 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 25th:
The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.
AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
by Zacks Equity Research
Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.
Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings?
by Zacks Equity Research
Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).